Targeted therapies for rare lung diseases


Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.


Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.



November 28, 2022

Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Read more »

October 17, 2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
Read more »

October 27, 2021

Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
Read more »

May 24, 2021

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Read more »

October 16, 2020

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Read more »

April 27, 2020

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Read more »

May 15, 2017

Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
Read more »

October 31, 2016

IPF Up and Comers Look to Add On Rather Than Compete
Read more »

September 3, 2014

Will Little-Known Company’s Inhaled Candidate Take Down InterMune-Roche’s Pirfenidone?
Read more »

August 5, 2014

Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Read more »

May 13, 2014

Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference
Read more »

April 21, 2014

Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability
Read more »